- Conditions
- Electronic Cigarette Related Lung Damage
- Interventions
- Cardiopulmonary Stress Test, Chest CT, Hyperpolarized xenon 129, Pulmonary Function Test
- Diagnostic Test · Drug
- Lead sponsor
- Y. Michael Shim, MD
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2032
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2017–2040
of 4,611
matching trials from the local directory fallback.
- Conditions
- Aging, Inflammation, Osteoporosis
- Interventions
- Placebo, SBD111 medical food
- Other
- Lead sponsor
- Hebrew SeniorLife
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Roslindale, Massachusetts
- Conditions
- High Grade Neuroendocrine Carcinoma, Any Site, Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma
- Interventions
- Hyperpolarized 13C-Pyruvate, Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acral Melanoma, Adrenocortical Carcinoma, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Paraganglioma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pheochromocytoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Thyroid Cancer, Uveal Melanoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate, Fludeoxyglucose F-18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Anusha Kalbasi
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Stanford, California
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- HLX13, OPDIVO, Yervoy
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Glendale, California • Jacksonville, Florida • Margate, Florida + 7 more
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
- Interventions
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
- Biological · Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Aspirin 162 mg, Aspirin 325mg, Aspirin 81mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Autonomic Failure, Dementia With Lewy Bodies, Multiple System Atrophy, Parkinson Disease, Pure Autonomic Failure
- Interventions
- Carbidopa 200mg oral dose, Entacapone 400mg oral dose, [18F]FDOPA
- Drug
- Lead sponsor
- Daniel Claassen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Burns
- Interventions
- Investigational Drug, MW-III, Silvadene® Cream 1% [Silver Sulfadiazine]
- Drug
- Lead sponsor
- Skingenix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 1 more
- Conditions
- Acute Kidney Injury, Heart Failure
- Interventions
- Dapagliflozin 10mg Tab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Aging, Type 2 Diabetes
- Interventions
- Intermittent Hypoxia 1 (IH1), Intermittent Hypoxia 2 (IH2), SHAM - normoxia
- Other
- Lead sponsor
- Darren P Casey
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Advanced Solid Tumors
- Interventions
- Fulvestrant, Palbociclib, SNV4818
- Drug
- Lead sponsor
- Pikavation Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
- Interventions
- MT-201, MT-501
- Drug
- Lead sponsor
- Mirador Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
- Conditions
- Diabetic Foot Ulcer
- Interventions
- NeoThelium FT (HCT/P 361)
- Other
- Lead sponsor
- NuScience Medical Biologics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Alexandria, Louisiana • Leesville, Louisiana • Many, Louisiana
- Conditions
- Age-Related (Dry) Macular Degeneration
- Interventions
- Retina imaging device (MSI-120) and AI (DeepMSI AI)
- Device
- Lead sponsor
- AI-Spectral
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Woodbridge, New Jersey
- Conditions
- Non-castrate Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Prostate Cancer Patients, Recurrent Prostate Cancer
- Interventions
- Anti-PD-1 monoclonal antibody, pTVG-HP DNA vaccine
- Drug · Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Kidney Disease
- Interventions
- NNC0519-0130, Placebo, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 18
- States / cities
- San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more
- Conditions
- Prostate Cancer
- Interventions
- 1.5 T Elekta Unity MR-Linac system, Hydrogel rectal spacer (SpaceOAR)
- Radiation · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- High Grade Glioma, MGMT-Methylated Glioblastoma, MGMT-Unmethylated Glioblastoma
- Interventions
- DB107-FC, DB107-RRV, Magnetic Resonance Imaging (MRI), Radiation Therapy (RT), Surgical resection, Temozolomide
- Drug · Genetic · Procedure + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 2 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoid Leukemia
- Interventions
- CD19 Directed CAR T Cell
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Eustachian Tube Dysfunction
- Interventions
- Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray
- Drug · Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more
- Conditions
- Prostate Carcinoma
- Interventions
- Biopsy of Prostate, Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Positron Emission Tomography
- Procedure · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Major Depressive Disorder, Parkinson's Disease
- Interventions
- 11C-UCB-J, ketamine hydrochloride
- Radiation · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut